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Objectives The goal of this study was to assess the procedural and 2-year results of the subclavian approach for transcatheter
aortic valve implantation (TAVI) compared with those of the femoral approach by using propensity-matched analysis.
Background The subclavian approach with the CoreValve prosthesis (Medtronic, Inc., Minneapolis, Minnesota) represents an
interesting opportunity when the femoral access is unfeasible.
Methods All consecutive patients enrolled in the Italian CoreValve Registry who underwent TAVI with the subclavian approach
were included. Propensity score analysis was used to identify a matching group of patients undergoing femoral TAVI.
Results Subclavian approach was used in 141 patients (61% men; median age 83 years; median logistic European Sys-
tem for Cardiac Operative Risk Evaluation score 23.7%). The femoral group of 141 patients was matched for
baseline clinical characteristics, except for peripheral artery disease. The 2 groups showed similar procedural
success (97.9% vs. 96.5%; p  0.47), major vascular complications (5.0% vs. 7.8%; p  0.33), life-threatening
bleeding events (7.8% vs. 5.7%; p  0.48), and combined safety endpoint (19.9% vs. 25.5%; p  0.26). The sub-
clavian group showed lower rates of acute kidney injury/stage 3 (4.3% vs. 9.9%; p  0.02), of minor vascular
complications at the 18-F sheath insertion site (2.1% vs. 11.3%; p  0.003), and of all types of bleeding events
related to vascular complications. Survival at 2 years was 74.0  4.0% in the subclavian group compared with
73.7  3.9% in the femoral group (p  0.78). The 2-year freedom from cardiovascular death was 87.2  3.1%
versus 88.7  2.8% in the subclavian versus femoral group, respectively (p  0.84).
Conclusions The subclavian approach for TAVI is safe and feasible, with procedural and medium-term results similar to the
femoral approach. Subclavian access should be considered a valid option not only when the femoral approach is
impossible but also when it is difficult, albeit feasible. (J Am Coll Cardiol 2012;60:502–7) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.014About one-third of candidates for transcatheter aortic valve
implantation (TAVI) suffer from severe peripheral artery
disease, making the routine femoral approach difficult or
impossible. Currently, the alternatives to the femoral ap-
proach are the transapical (1), the subclavian (2), and the
direct aortic access (3). In the current study, we report the
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Patient population. Since June 2007, all consecutive pa-
tients undergoing TAVI with the 18-F CoreValve prosthe-
sis at 13 Italian centers were prospectively enrolled in the
Italian CoreValve Registry. Patient eligibility criteria, reg-
istry design, and technical details of the procedure have been
described elsewhere (2,4,5). The study was approved by the
institutional ethics committees, and written informed con-
sent was obtained from all patients.
Since January 2008, all patients with small (diameter 6
mm) or severely diseased iliofemoral arteries were evaluated
for the feasibility of the subclavian approach by means of
angiography, multislice computed tomography, and Duplex
ultrasound. Subclavian access was excluded in case of vessel
diameter 6 mm, heavy calcifications, excessive tortuosity,
and severe stenosis not amenable to balloon angioplasty.
Presence of a permanent pacemaker in the left pectoral
region was not considered a contraindication, nor was the
presence of a patent left internal mammary artery (LIMA)
coronary graft, provided that the subclavian artery diameter
was 7 mm.
The subclavian TAVI technique and anesthetic manage-
ment have been described previously (2,6).
Definitions. In October 2011, the information contained
in the web-based registry were re-evaluated by the Steering
Committee to conform to the definitions proposed by the
Valve Academic Research Consortium (7). Device success,
all-cause mortality, cardiovascular mortality, myocardial in-
farction, stroke, vascular complications, bleeding complica-
tions, 30-day combined safety endpoint, and 2-year com-
bined efficacy endpoint were re-assessed.
Statistical analysis. Continuous variables are presented as
mean  SD or as median (interquartile range) and were
compared using the 2-tailed Student t test or the Mann-
Whitney U test, as appropriate. Categorical variables were
compared by using the chi-square test or Fisher exact test, as
appropriate. The cumulative incidences of clinical events at
follow-up were assessed by using the Kaplan-Meier
method, and the log-rank test was used for comparison
between groups. A p value 0.05 was considered statisti-
cally significant.
To identify a comparable group of patients undergoing
femoral TAVI, propensity analysis was performed on 927
femoral patients enrolled in the Italian CoreValve Registry.
The propensity score was calculated by using a logistic
regression model that included the following variables: age,
sex, coronary artery disease, pulmonary hypertension, pre-
vious aortic valvuloplasty, previous stroke, left ventricular
ejection fraction, and serum creatinine 2.0 mg/dl. Match-
ing was performed by randomly selecting a subclavian
patient and looking for the femoral patient with the nearest
logit-transformed propensity score.
All data were processed using SPSS version 15.0 (SPSS
Inc., Chicago, Illinois).Results
Patient population. Between
June 2007 and March 2011, a
total of 141 of 1,068 consecutive
patients enrolled in the Italian
CoreValve Registry were treated
with the subclavian access in 10
centers, with a median number of 8 cases (range 4 to 36).
The overall rate of subclavian access in the registry rose from
9.0% in 2008 to 20.0% in 2011. The propensity score used
to identify a matched femoral access cohort showed a good
discriminative power (C-statistic 0.70). Baseline demo-
graphic characteristics were similar between the 2 groups
(Table 1), except for peripheral artery disease, which was
more prevalent in the subclavian group (p  0.0001).
Twelve patients (8.5%) of the subclavian group had a patent
LIMA.
Procedural results. The left subclavian artery was used in
96% of subclavian patients. Device success was similarly
high in both groups (p  0.47), with a lower rate of local
anesthesia in the subclavian group (p  0.0001) (Table 2).
Overall procedural time was longer in the subclavian group
because of the surgical vascular access (p 0.0001), whereas
fluoroscopy time was similar (p  0.15).
Procedural mortality was very low in both groups (p 
0.56). No patient with a patent LIMA undergoing TAVI
through the left subclavian artery showed signs of myocar-
dial ischemia during the procedure. In addition, no brachial
plexus injuries were observed.
In-hospital outcome. In-hospital events are defined in
Table 3. Mortality was entirely due to cardiovascular causes
and was similar between groups (p 0.78), as well as stroke,
myocardial infarction, new left bundle branch block, and
new permanent pacemaker implantation. Conversely, the
rate of acute kidney injury/stage 3 was significantly lower in
the subclavian group (p  0.02).
Abbreviations
and Acronyms
LIMA  left internal
mammary artery
TAVI  transcatheter aortic
valve implantation
Demographic CharacteristicsTable 1 Demographic Characteristics
Characteristic
Subclavian
Access
Femoral
Access p Value
Age (yrs) 83.0 (78.9–87.0) 83.0 (78.6–86.1) 0.25
Female 55 (39.0) 60 (42.3) 0.54
Logistic EuroSCORE 23.7 (15.8–33.6) 23.3 (13.5–32.7) 0.32
Peripheral artery disease 120 (85.1) 29 (20.6) 0.0001
Coronary artery disease 83 (58.9) 69 (48.9) 0.09
Previous coronary
revascularization
68 (48.2) 53 (37.6) 0.07
Previous stroke 18 (12.8) 13 (9.2) 0.34
Serum creatinine 2 mg/dl 19 (13.5) 12 (8.5) 0.24
NYHA functional class III/IV 102 (72.3) 96 (68.0) 0.86
Left ventricular ejection
fraction (%)
54 (41–60) 52 (40–60) 0.27
Peak aortic gradient (mm Hg) 82.4 20.8 81.9 21.4 0.83
Mean aortic gradient (mm Hg) 50.2 14.2 50.1 14.1 0.96
Values are median (interquartile range), n (%), or mean  SD.
EuroSCORE European System for Cardiac Operative R
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Subclavian Access for TAVI: 2-Year Results August 7, 2012:502–7The rates of major vascular complications (p  0.33) and
minor vascular complications (p  0.16) were similar
etween groups. In particular, the major subclavian artery
omplications were as follows: tear of the vessel wall at the
ite of sheath insertion in 3 cases, requiring covered stent
mplantation in 2 cases and prolonged external hemostasis
n 1; longitudinal vessel dissection in 3 cases, requiring stent
mplantation in 2; and acute asymptomatic subclavian
hrombosis in 1 case, resolved with local thrombolytic
dministration. Of note, minor vascular complications in
he subclavian group were often related to the simultaneous
-F femoral access; consequently, minor vascular complica-
ions at the site of 18-F sheath insertion were significantly
ower in the subclavian group (p  0.003) (Fig. 1).
All types of bleeding complications were also similar
etween groups (Table 3). When considering only bleeding
vents directly related to vascular complications at 18-F
heath insertion sites, the subclavian group displayed a
ignificantly lower rate of life-threatening (p  0.05), major
p  0.04), and minor (p  0.02) (Fig. 2) bleeding events.
Rates of new permanent pacemaker implantation and of
ew left bundle branch block were similar between groups,
In-Hospital OutcomeTable 3 In-Hospital Outcome
Outcome
Subclavian
Access
Femoral
Access p Value
All-cause mortality 7 (5.0) 6 (4.3) 0.78
Stroke 3 (2.1) 3 (2.1) 0.99
Myocardial infarction 0 (0) 0 (0) 0.99
Major vascular complications 7 (5.0) 11 (7.8) 0.33
Minor vascular complications 10 (7.1) 17 (12.1) 0.16
18-F access-related 3 (2.1) 16 (11.3) 0.003
Life-threatening bleeding events 11 (7.8) 8 (5.7) 0.48
18-F vascular complication–related 1 (0.7) 6 (4.3) 0.05
Major bleeding events 51 (36.2) 43 (30.5) 0.31
18-F vascular complication–related 4 (2.8) 12 (8.5) 0.04
Minor bleeding events 13 (9.2) 12 (8.5) 0.83
18-F vascular complication–related 1 (0.7) 8 (5.7) 0.02
Acute kidney injury/stage 3 6 (4.3) 14 (9.9) 0.02
New left bundle branch block 35 (24.8) 30 (21.3) 0.49
New permanent pacemaker 34 (24.1) 33 (23.4) 0.88
Procedural ResultsTable 2 Procedural Results
Outcome
Subclavian
Access
Femoral
Access p Value
Device success 138 (97.9) 136 (96.5) 0.47
Procedural mortality 2 (1.4) 1 (0.7) 0.56
Local anesthesia 65 (46.1) 118 (83.7) 0.0001
Fluoroscopy time (min) 18 (14–27) 21 (15–30) 0.15
Procedural time (min) 120 (89–127) 75 (60–120) 0.0001
29-mm CoreValve* 80 (56.7) 71 (50.4) 0.28
CoreValve-in-CoreValve 2 (1.4) 6 (4.3) 0.17
CoreValve migration 1 (0.7) 1 (0.7) 0.96
Conversion to surgery 1 (0.7) 1 (0.7) 0.99
Values are n (%) or median (interquartile range). *Medtronic, Inc., Minneapolis, Minnesota.Values are n (%).s well as the rate of more than mild paravalvular leak
17.9% vs. 17.7%; p  0.91).
0-day outcome. Thirty-day outcomes were available for
ll patients and are defined in Table 4. All-cause mortality
p  0.80) and cardiovascular mortality (p  0.79) were
similar between groups. The combined safety endpoint
(all-cause mortality, major stroke, life-threatening bleeding,
acute kidney injury/stage 3, myocardial infarction, major
vascular complication, and reintervention for valve-related
dysfunction) was also similar between subclavian and fem-
oral patients (p  0.26).
Long-term outcome. Two-year follow-up data were avail-
able in 95.7% of patients, with survival status reported as of
September 30, 2011. Median follow-up in the subclavian
and femoral groups was 17 (range 8 to 27) months and 20
(range 8 to 31) months, respectively. The Kaplan-Meier
survival curve for the 2 groups is shown in Figure 3. Survival
Figure 1 Vascular Complications
Major and minor vascular complications related to the 18-F access.
Figure 2 Bleeding Complications
Bleeding events related to vascular complications at the site of 18-F access.
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August 7, 2012:502–7 Subclavian Access for TAVI: 2-Year Resultsat 2 years was 74.0  4.0% in the subclavian group
compared with 73.7  3.9% in the femoral group (p 
0.78). The 2-year freedom from cardiovascular death was
87.2  3.1% versus 88.7  2.8% in the subclavian versus
femoral group, respectively (p  0.84) (Fig. 4). Between 30
days and 2 years, 3 subclavian and 2 femoral patients
underwent aortic valve reintervention; 14 subclavian and 10
femoral patients required rehospitalization for cardiac
causes; 2 femoral patients developed prosthetic valve dys-
function; and 1 subclavian patient required pacemaker
implantation. The 2-year freedom from the combined
efficacy endpoint (all-cause mortality after 30 days, hospi-
talization for valve-related or cardiac decompensation, and
prosthetic valve dysfunction) was 71.7  4.3% versus 71.4 
4.1% in the subclavian versus the femoral group, respectively
(p  0.78) (Fig. 5).
Discussion
This is the first report to the best of our knowledge on the
medium-term results of TAVI with the CoreValve through
the subclavian access in the largest cohort of patients
described so far. Importantly, the subclavian population was
compared with a propensity-matched femoral cohort of
patients.
Clinical Outcomes at 30 DaysTable 4 Clinical Outcomes at 30 Days
Outcome Subclavian Access Femoral Access p Value
All-cause mortality 8 (5.7) 9 (6.4) 0.80
Cardiac mortality 8 (5.7) 7 (5.0) 0.79
Cardiac rehospitalization 2 (1.4) 2 (1.4) 0.99
Stroke 3 (2.1) 3 (2.1) 0.99
Myocardial infarction 0 (0) 0 (0) 0.99
Aortic valve reintervention 0 (0) 1 (0.7) 0.31
Combined safety endpoint 28 (19.9) 36 (25.5) 0.26
New pacemaker 35 (24.7) 35 (24.7) 0.99
Values are n (%).
Figure 3 Kaplan-Meier Estimates of 2-Year Survival
Red line  subclavian group; blue line  femoral group.Peripheral artery disease, ranging from 19% to 42% in
patients undergoing TAVI (4,8–10), often makes the fem-
oral access difficult or even impossible. Thus, alternative
access routes have been proposed; namely, the transapical
(1), subclavian/axillary (2), and direct aortic access (3).
We previously reported the early results of the subclavian
access in the initial 54 patients from the Italian CoreValve
Registry, demonstrating excellent procedural success, low
in-hospital complications, and good 6-month survival (2).
In the current study, we report the 2-year results in a tripled
subclavian population compared with a propensity score–
matched femoral population. In fact, patients with contra-
indications to the femoral access usually experience more
comorbidities and have a higher surgical risk (2,11).
Procedural results. Procedural success was excellent in
both groups, confirming that TAVI can be performed
Figure 4 Freedom From Cardiovascular Death
Kaplan-Meier estimates of 2-year freedom from cardiovascular death.
Red line  subclavian group; blue line  femoral group.
Figure 5 Freedom From Combined Efficacy Endpoint
Kaplan-Meier estimates of 2-year freedom from combined efficacy endpoint.
Red line  subclavian group; blue line  femoral group.
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Subclavian Access for TAVI: 2-Year Results August 7, 2012:502–7through the subclavian route without additional procedural
risks. Although technically more demanding, the right
subclavian access was successful in 6 of 6 patients. The
technique used for the subclavian access was uniform, with
direct puncture of the artery in 95.7% of the cases. Impor-
tantly, use of local anesthesia rose from 25.0% in the first 4
cases per center to 56.2% subsequently (p  0.004). The
possibility of using local anesthesia is an important advan-
tage over the transapical and direct aortic access, considering
the risks of general anesthesia in elderly patients who suffer
from multiple comorbidities (6).
Vascular complications. The large-bore arterial sheaths
required for TAVI entail a relevant risk of vascular access
complications, which have an important negative impact on
outcome (4,10). The development of lower profile devices
allowed for a decrease in vascular complications with respect
to the initial experience; however, the rate of major vascular
injuries in contemporary TAVI registries ranges from 2.0%
to 22.9%, depending on the definitions used (4,8,12). The
standardization of endpoint definitions recently proposed by
the Valve Academic Research Consortium represents a
cornerstone for current and future studies (7) and was
adopted in the Italian CoreValve Registry soon after its
publication. In our study, the incidence of major and minor
vascular complications was acceptably low and similar be-
tween subclavian and femoral patients. However, minor
vascular complications related to the 18-F access were
significantly lower in the subclavian group (p  0.003).
imilarly, when considering only bleeding events related to
n 18-F site complication, the rates of all types of bleeding
vents were significantly lower in the subclavian group.
hese findings demonstrate the safety of this approach,
hich can be accomplished without increased risks of
ascular injury and bleeding.
arly and long-term outcome. In-hospital and 30-day
dverse events were low in both groups, including mortality,
troke, and myocardial infarction. The rate of new perma-
ent pacemaker implantation was also similar between
roups. Of notice, subclavian patients displayed a signifi-
antly lower rate of acute kidney injury/stage 3 (p  0.02),
robably related to the higher amount of contrast medium
dministered with the femoral approach due to the need for
ngiographic control of the iliofemoral arteries.
The 2-year Kaplan-Meier survival was 74% in both
roups, which is within the 61.9% to 73.7% range reported
n the literature (8,13). This finding demonstrates that the
hoice of the subclavian access did not negatively affect
ong-term survival. Importantly, the 2-year survival in our
ubclavian TAVI experience compares favorably with the
3.3% survival reported for the nontransfemoral cohort
85% transapical) of the UK TAVI registry. In addition,
he transapical approach is definitely more invasive, man-
ates general anesthesia, and entails additional specific risks,
ncluding chest re-exploration, left ventricular false aneu-
ysm, and apical akinesia (11).Our survival data showed a marked attrition in the first 6
onths after TAVI, in addition to 30-day mortality, which
s in agreement with most studies (5,8–11). This flattening
f the Kaplan-Meier curve after 6-month post-intervention
as more evident regarding freedom from cardiovascular
eath, which was high in both groups at 2 years (87.2 
.1% vs. 88.7 2.8%; p 0.84). Such discrepancy between
ll-cause and cardiovascular mortality is frequently reported
n TAVI patients (5,9) who often have severe comorbidities
hat may lead to death even a few months after TAVI.
urther investigation is warranted to prospectively identify
hose candidates who have dismal short-term prognosis,
ndependent of their aortic valve stenosis.
tudy limitations. The Italian CoreValve registry has in-
ependent monitoring and event adjudication; however,
ata are self-reported and have not been systematically
alidated. In addition, the data were re-evaluated to con-
orm to the Valve Academic Research Consortium criteria.
inally, the comparison between the subclavian and femoral
ohorts was propensity matched but not randomized.
onclusions
utcomes after TAVI through the subclavian access in this
igh-risk population were encouraging and similar to those
f TAVI through the femoral approach. In addition, vas-
ular and bleeding complications directly related to the 18-F
rterial access were lower in the subclavian cohort, and no
pecific subclavian complication was observed. These results
uggest that the subclavian access represents a valid alter-
ative not only when the femoral access is contraindicated
ut also when it appears difficult, albeit feasible.
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